Watch full video<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"Albert Hwa, Operations Director at the Joslin’s Center for Cell-Based Therapy for Diabetes (CCTD) and Lecturer the Harvard Medical School, discusses the pro and cons of shielding stem-cell derived \u03b2-Cells with alginate, versus strategies aiming at reducing the immunogenicity of transplanted cells. <\/p>\n","protected":false},"author":1,"featured_media":2495,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_mi_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[4],"tags":[],"aioseo_notices":[],"yoast_head":"\n
Cell Therapy for Diabetes : immune tolerance vs shielded strategies - Stem Cells & Cell Therapy Blog I In the Stem Cell Jungle I iPSCs I TreeFrog Therapeutics<\/title>\n\n\n\n\n\n\n\n\n\n\n\t\n\t\n\t\n\n\n\n\n